Literature DB >> 16789756

New 2',6'-dimethyl-L-tyrosine (Dmt) opioid peptidomimetics based on the Aba-Gly scaffold. Development of unique mu-opioid receptor ligands.

Steven Ballet1, Severo Salvadori, Claudio Trapella, Sharon D Bryant, Yunden Jinsmaa, Lawrence H Lazarus, Lucia Negri, Elisa Giannini, Roberta Lattanzi, Dirk Tourwé, Gianfranco Balboni.   

Abstract

The Aba-Gly scaffold, incorporated into Dmt-Tic ligands (H-Dmt-Tic-Gly-NH-CH2-Ph, H-Dmt-Tic-Gly-NH-Ph, H-Dmt-Tic-NH-CH2-Bid), exhibited mixed micro/delta or delta opioid receptor activities with micro agonism. Substitution of Tic by Aba-Gly coupled to -NH-CH2-Ph (1), -NH-Ph (2), or -Bid (Bid=1H-benzimidazole-2-yl) (3) shifted affinity (Ki(micro)=0.46, 1.48, and 19.9 nM, respectively), selectivity, and bioactivity to micro-opioid receptors. These compounds represent templates for a new class of lead opioid agonists that are easily synthesized and suitable for therapeutic pain relief.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16789756      PMCID: PMC2983084          DOI: 10.1021/jm0603264

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  46 in total

1.  Assessment of substitution in the second pharmacophore of Dmt-Tic analogues.

Authors:  V Santagada; G Balboni; G Caliendo; R Guerrini; S Salvadori; C Bianchi; S D Bryant; L H Lazarus
Journal:  Bioorg Med Chem Lett       Date:  2000-12-18       Impact factor: 2.823

2.  Neuroprotective role of delta-opioid receptors in cortical neurons.

Authors:  Junhui Zhang; Geoffrey Thomas Gibney; Peng Zhao; Ying Xia
Journal:  Am J Physiol Cell Physiol       Date:  2002-06       Impact factor: 4.249

3.  Novel C-terminus modifications of the Dmt-Tic motif: a new class of dipeptide analogues showing altered pharmacological profiles toward the opioid receptors.

Authors:  D Pagé; A Naismith; R Schmidt; M Coupal; M Labarre; M Gosselin; D Bellemare; K Payza; W Brown
Journal:  J Med Chem       Date:  2001-07-19       Impact factor: 7.446

4.  Evaluation of the Dmt-Tic pharmacophore: conversion of a potent delta-opioid receptor antagonist into a potent delta agonist and ligands with mixed properties.

Authors:  Gianfranco Balboni; Remo Guerrini; Severo Salvadori; Clementina Bianchi; Daniela Rizzi; Sharon D Bryant; Lawrence H Lazarus
Journal:  J Med Chem       Date:  2002-01-31       Impact factor: 7.446

5.  Structural studies of [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues: enhanced activity and cis orientation of the Dmt-Pro amide bond.

Authors:  Yoshio Okada; Yoshio Fujita; Takashi Motoyama; Yuko Tsuda; Toshio Yokoi; Tingyou Li; Yusuke Sasaki; Akihiro Ambo; Yunden Jinsmaa; Sharon D Bryant; Lawrence H Lazarus
Journal:  Bioorg Med Chem       Date:  2003-05-01       Impact factor: 3.641

6.  Further studies on the Dmt-Tic pharmacophore: hydrophobic substituents at the C-terminus endow delta antagonists to manifest mu agonism or mu antagonism.

Authors:  S Salvadori; R Guerrini; G Balboni; C Bianchi; S D Bryant; P S Cooper; L H Lazarus
Journal:  J Med Chem       Date:  1999-12-02       Impact factor: 7.446

7.  Potent delta-opioid receptor agonists containing the Dmt-Tic pharmacophore.

Authors:  Gianfranco Balboni; Severo Salvadori; Remo Guerrini; Lucia Negri; Elisa Giannini; Yunden Jinsmaa; Sharon D Bryant; Lawrence H Lazarus
Journal:  J Med Chem       Date:  2002-12-05       Impact factor: 7.446

8.  The opioid mu agonist/delta antagonist DIPP-NH(2)[Psi] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats.

Authors:  P W Schiller; M E Fundytus; L Merovitz; G Weltrowska; T M Nguyen; C Lemieux; N N Chung; T J Coderre
Journal:  J Med Chem       Date:  1999-09-09       Impact factor: 7.446

9.  New scaffolds in the development of mu opioid-receptor ligands.

Authors:  Daniel Pagé; Natalie Nguyen; Sylvain Bernard; Martin Coupal; Mylène Gosselin; Julie Lepage; Lynda Adam; William Brown
Journal:  Bioorg Med Chem Lett       Date:  2003-05-05       Impact factor: 2.823

Review 10.  Dmt and opioid peptides: a potent alliance.

Authors:  Sharon D Bryant; Yunden Jinsmaa; Severo Salvadori; Yoshio Okada; Lawrence H Lazarus
Journal:  Biopolymers       Date:  2003       Impact factor: 2.505

View more
  6 in total

1.  Synthesis, pharmacological evaluation and conformational investigation of endomorphin-2 hybrid analogues.

Authors:  Giordano Lesma; Severo Salvadori; Francesco Airaghi; Engin Bojnik; Anna Borsodi; Teresa Recca; Alessandro Sacchetti; Gianfranco Balboni; Alessandra Silvani
Journal:  Mol Divers       Date:  2012-11-04       Impact factor: 2.943

2.  Novel multiple opioid ligands based on 4-aminobenzazepinone (Aba), azepinoindole (Aia) and tetrahydroisoquinoline (Tic) scaffolds.

Authors:  Steven Ballet; Ewa D Marczak; Debby Feytens; Severo Salvadori; Yusuke Sasaki; Andrew D Abell; Lawrence H Lazarus; Gianfranco Balboni; Dirk Tourwé
Journal:  Bioorg Med Chem Lett       Date:  2010-01-20       Impact factor: 2.823

3.  Role of 2',6'-dimethyl-l-tyrosine (Dmt) in some opioid lead compounds.

Authors:  Gianfranco Balboni; Erika Marzola; Yusuke Sasaki; Akihiro Ambo; Ewa D Marczak; Lawrence H Lazarus; Severo Salvadori
Journal:  Bioorg Med Chem       Date:  2010-06-25       Impact factor: 3.641

4.  Conformationally constrained opioid ligands: the Dmt-Aba and Dmt-Aia versus Dmt-Tic scaffold.

Authors:  Steven Ballet; Debby Feytens; Rien De Wachter; Magali De Vlaeminck; Ewa D Marczak; Severo Salvadori; Chris de Graaf; Didier Rognan; Lucia Negri; Roberta Lattanzi; Lawrence H Lazarus; Dirk Tourwé; Gianfranco Balboni
Journal:  Bioorg Med Chem Lett       Date:  2008-11-19       Impact factor: 2.823

Review 5.  Peptidomimetics and Their Applications for Opioid Peptide Drug Discovery.

Authors:  Yeon Sun Lee
Journal:  Biomolecules       Date:  2022-09-05

6.  In silico study on binding specificity of gonadotropins and their receptors: design of a novel and selective peptidomimetic for human follicle stimulating hormone receptor.

Authors:  Archana Sonawani; Sarfaraj Niazi; Susan Idicula-Thomas
Journal:  PLoS One       Date:  2013-05-20       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.